𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Sa1200 Presence and Concentration of OmpC As a Risk Factor for Developing Antibodies to Infliximab (ATI): Implications for Selecting Patients With Inflammatory Bowel Disease (IBD) for Combination Therapy

✍ Scribed by Lockton, Steven; Shah, Dhara; Princen, Fred; Hauenstein, Scott; Singh, Sharat; Levesque, Barrett G.; Sandborn, William; Feaga, Brian G.


Book ID
122074265
Publisher
Elsevier Science
Year
2014
Tongue
English
Weight
378 KB
Volume
146
Category
Article
ISSN
0016-5085

No coin nor oath required. For personal study only.